Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Please find attached the details of the proposed schedule of Analyst/Institutional Investor meeting. Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Please find attached the details of the proposed schedule of Analyst/Institutional Investor meeting. F&O Strategy: Buy Dr Lal Path Labs call option
Traders can go long on May expiry 2100-strike call option, which closed at 29.40 Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 and 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached the copy of newspaper advertisement of Financial Results of the Company for the Quarter and Financial Year ended March 31, 2023, published in Financial Express and Jansatta on May 12, 2023.
Dr Lal PathLabs stock under pressure after March quarter earnings fails to impress
Dr Lal PathLabs Ltd reported 8.2 percent year on year decline in net profit for the March quarter to Rs 57 crore from Rs 62 crore. Revenue rose just 1.1 percent to Rs 491 crore from a year ago. Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to Regulation 30 and 46(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please note that the audio recording of the Company's Conference Call dated May 11, 2023 with Investors/ Analysts for Q4 & FY23 is available on the Company's website at https://www.lalpathlabs.com/investors/investors-inside/quarterly-result Dr. Lal PathLabs Ltd - 539524 - Disclosure Of Related Party Transactions For The Half Year Ended March 31, 2023
Pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. SEBI/HO/CFD/CMD1/CIR/P/2021/662 dated November 22, 2021, please find enclosed herewith the Disclosure of Related Party Transactions for the half year ended March 31, 2023.
Dr. Lal Pathlabs Results Earnings Call for Q4FY23
Conference Call with Dr. Lal Pathlabs Management and Analysts on Q4FY23 Performance and Outlook. Listen to the full earnings transcript. Q4FY23 Quarterly & FY23 Annual Result Announced for Dr. Lal Pathlabs Ltd.
Healthcare Services company Dr. Lal Pathlabs announced Q4FY23 & FY23 results: Dr. Lal PathLabs records revenue of Rs 491 crore in Q4FY23 Non-Covid Revenue increased by 14.4% in Q4FY23 & 15.5% in FY23 Normalised EBITDA margin (after adjustment for stock-based compensation, CSR & exceptional expenses) for Q4FY23 is 26.6% & 26.2% for FY23 The normalised PAT margin for Q4FY23 is 15.5% and 14.7% for FY23 Result PDF Dr. Lal PathLabs Ltd - 539524 - Appointment of Company Secretary and Compliance Officer
Please take note that the Board of Directors in their meeting held today i.e. May 11, 2023 inter-alia approved the Appointment of Mr. Vinay Gujral as Company Secretary (KMP) of the Company w.e.f. May 11, 2023;